A Study of ResCure™ to Treat COVID-19 Infection

Purpose

This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.

Conditions

  • COVID
  • Covid-19
  • Corona Virus Infection
  • Sars-CoV2
  • Coronavirus-19
  • SARS Pneumonia
  • SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Critically ill patients with SARS from COVID-19 infection on respirators OR 2. Patients with SARS from COVID-19 infection prior or after being placed on respirator 3. Male or female patients 18 years of age and older

Exclusion Criteria

  1. Patients less than 18 years of age

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Treatment Group 		This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.
  • Biological: ResCure™
    Patients will be treated with nebulized ResCure™

Recruiting Locations

More Details

NCT ID
NCT04395716
Status
Withdrawn
Sponsor
ProgenaBiome

Detailed Description

In this Phase I open-label interventional study we will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection. Patients being treated will have severe respiratory symptoms that are at or near requiring the patient be placed on a ventilator.